Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA Monitoring in Risk Stratified PTLD
NCT06954805Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Targeted Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, etoposide, prednisone, vincristine sulfate liposome injection, cyclophosphamide in lymphoproliferative disorder (LPD). Started Apr 2025; status: recruiting.
02
Drugs
rituximabetoposideprednisonevincristine sulfate liposome injectioncyclophosphamide
03
Conditions
lymphoproliferative disorder (LPD)
Beyond the preview
Go deeper on NCT06954805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954805.